Articlenpj biomedical innovations2026
Contactless 12-lead electrocardiogram via deep computational radar.
Article in npj biomedical innovations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- AI-Enabled Sensor Technologies for Remote Arrhythmic Monitoring in High-Risk Cardiomyopathy Genotypes.Sensors (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) remains the leading cause of global mortality, highlighting the need for scalable, continuous, and contactless diagnostics. Traditional electrocardiogram (ECG) systems, though essential for detecting cardiac abnormalities, are constrained by contact-based, intermittent measurements. In this work, we introduce CardioRadar, a clinically validated radar-based system for contactless 12-lead ECG monitoring. Compact custom radar hardware captures chest micro-motions induced by cardiac activity, while data-driven inverse modeling reconstructs electrical signals from mechanical motion. Validated in 6974 individuals across diverse clinical settings, CardioRadar achieves a mean correlation of 0.75 (median: 0.77), RMSE of 0.09 mV (median: 0.07 mV), and inter-beat interval error of 23.39 ms (median: 5.60 ms) compared to ground-truth ECG. It also reliably detects arrhythmias and supports continuous overnight monitoring. CardioRadar represents a transformative, low-cost solution for equitable, long-term cardiovascular care.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.